Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 401–500 of 15,747
Halperin, S. A., Ye, L., MacKinnon-Cameron, D., Smith, B., Cahn, P. E., Ruiz-Palacios, G. M., Ikram, A., Lanas, F., Lourdes Guerrero, M., Muñoz Navarro, S. R., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02753-7 · Cited by 225
Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar
Chemaitelly, H., Ayoub, H. H., AlMukdad, S., Coyle, P., Tang, P., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Hasan, M. R., Al-Kanaani, Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30895-3 · Cited by 228
Circulating Spike Protein Detected in Post–COVID-19 mRNA Vaccine Myocarditis
Yonker, L. M., Swank, Z., Bartsch, Y. C., Burns, M. D., Kane, A., Boribong, B. P., Davis, J. P., Loiselle, M., Novak, T., Senussi, Y., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.061025 · Cited by 224
Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes
Saad-Roy, C. M., Morris, S. E., Metcalf, C. J. E., Mina, M. J., Baker, R. E., Farrar, J., Holmes, E. C., Pybus, O. G., Graham, A. L., Levin, S. A., et al. (2021) · Science · doi:10.1126/science.abg8663 · Cited by 220
SARS-COV-2 Variants: Differences and Potential of Immune Evasion
Hirabara, S. M., Serdan, T. D. A., Gorjao, R., Masi, L. N., Pithon-Curi, T. C., Covas, D. T., Curi, R., & Durigon, E. L. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.781429 · Cited by 226
“For example, the mRNA-based BNT 162b2 vaccine (Pfizer/ BioNTech) reached 95% efficacy against the original SARS-CoV-2 infection (Polack et al., 2020).”
BackgroundChu, L., McPhee, R., Huang, W., Bennett, H., Pajon, R., Nestorova, B., & Leav, B. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.02.007 · Cited by 225
Bergman, P., Blennow, O., Hansson, L., Mielke, S., Nowak, P., Chen, P., Söderdahl, G., Österborg, A., Smith, C. I. E., Wullimann, D., et al. (2021) · eBioMedicine · doi:10.1016/j.ebiom.2021.103705 · Cited by 223
“There are currently two approved mRNA vaccines, showing a good safety profile and high vaccine efficacy with regards to prevention of SARS-CoV-2 infection and disease [4,5].”
BackgroundResultClimate change and infectious disease in Europe: Impact, projection and adaptation
Semenza, J. C., & Paz, S. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100230 · Cited by 225
Huang, Y., Wang, J., Jiang, K., & Chung, E. J. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.04.016 · Cited by 222
A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson
Patel, R., Kaki, M., Potluri, V. S., Kahar, P., & Khanna, D. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.2002083 · Cited by 223
“6% efficacy against infection.(14) While not the primary focus of the study, a vaccine efficacy of 52.”
BackgroundResultInfluentialPuranik, A., Lenehan, P. J., Silvert, E., Niesen, M. J. M., Corchado-Garcia, J., O’Horo, J. C., Virk, A., Swift, M. D., Halamka, J., Badley, A. D., et al. (2021) · medRxiv · doi:10.1101/2021.08.06.21261707 · Cited by 255
“The columns are: (1) Outcome: the clinical metric of COVID-19 severity assessed in the given row; (1) mRNA-1273 Breakthrough Cohort: cumulative incidence of the given outcome among mRNA-1273 breakthrough cases; (2) Prevalence in BNT162b2 Breakthrough Cohort: cumulative incidence of the given outcome among mRNA-1273 br…”
BackgroundMucosal immune response in BNT162b2 COVID-19 vaccine recipients
Azzi, L., Dalla Gasperina, D., Veronesi, G., Shallak, M., Ietto, G., Iovino, D., Baj, A., Gianfagna, F., Maurino, V., Focosi, D., et al. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2021.103788 · Cited by 219
A survey on COVID-19 vaccine acceptance and concern among Malaysians
Syed Alwi, S. A. R., Rafidah, E., Zurraini, A., Juslina, O., Brohi, I. B., & Lukas, S. (2021) · BMC Public Health · doi:10.1186/s12889-021-11071-6 · Cited by 220
“Therefore, a safe and effective prophylactic vaccine is urgently needed to contain the pandemic, which has had devastating medical, economic, and social repercussions [8].”
BackgroundLevine-Tiefenbrun, M., Yelin, I., Alapi, H., Katz, R., Herzel, E., Kuint, J., Chodick, G., Gazit, S., Patalon, T., & Kishony, R. (2021) · doi:10.1101/2021.08.29.21262798 · Cited by 222
“To calculate the change in Ct between post-vaccination time bins, we applied the same linear regression model as above, except replacing the length-5 onehot vector of post-vaccination time with a 3-length time-accumulated binary vector indicating [0,0,0], [1,0,0], [1,1,0], [1,1,1] for infections in unvaccinated, or 7-…”
MethodLevine-Tiefenbrun, M., Yelin, I., Alapi, H., Katz, R., Herzel, E., Kuint, J., Chodick, G., Gazit, S., Patalon, T., & Kishony, R. (2021) · Nature Medicine · doi:10.1038/s41591-021-01575-4 · Cited by 222
Chalmers, J. D., Crichton, M. L., Goeminne, P. C., Cao, B., Humbert, M., Shteinberg, M., Antoniou, K. M., Ulrik, C. S., Parks, H., Wang, C., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.00048-2021 · Cited by 219
The effect of spike mutations on SARS-CoV-2 neutralization
Rees-Spear, C., Muir, L., Griffith, S. A., Heaney, J., Aldon, Y., Snitselaar, J. L., Thomas, P., Graham, C., Seow, J., Lee, N., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108890 · Cited by 215
Inhalable dry powder mRNA vaccines based on extracellular vesicles
Popowski, K. D., Moatti, A., Scull, G., Silkstone, D., Lutz, H., López de Juan Abad, B., George, A., Belcher, E., Zhu, D., Mei, X., et al. (2022) · Matter · doi:10.1016/j.matt.2022.06.012 · Cited by 218
Chi, W.-Y., Li, Y.-D., Huang, H.-C., Chan, T. E. H., Chow, S.-Y., Su, J.-H., Ferrall, L., Hung, C.-F., & Wu, T.-C. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00853-8 · Cited by 215
“So far, no severe adverse event has been reported in randomized controlled trials in children and adolescents [15, 21, 22, 209].”
BackgroundSkelly, D. T., Harding, A. C., Gilbert-Jaramillo, J., Knight, M. L., Longet, S., Brown, A., Adele, S., Adland, E., Brown, H., Team, M. L., et al. (2021) · doi:10.21203/rs.3.rs-226857/v2 · Cited by 216
Skelly, D. T., Harding, A. C., Gilbert-Jaramillo, J., Knight, M. L., Longet, S., Brown, A., Adele, S., Adland, E., Brown, H., Team, M. L., et al. (2021) · doi:10.21203/rs.3.rs-226857/v1 · Cited by 216
Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection
Zhang, A., Stacey, H. D., D’Agostino, M. R., Tugg, Y., Marzok, A., & Miller, M. S. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00813-1 · Cited by 214
In vivo delivery of CRISPR-Cas9 therapeutics: Progress and challenges
Behr, M., Zhou, J., Xu, B., & Zhang, H. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.05.020 · Cited by 210
Review of COVID-19 vaccine subtypes, efficacy and geographical distributions
Francis, A. I., Ghany, S., Gilkes, T., & Umakanthan, S. (2022) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2021-140654 · Cited by 215
COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021
Achiron, A., Dolev, M., Menascu, S., Zohar, D.-N., Dreyer-Alster, S., Miron, S., Shirbint, E., Magalashvili, D., Flechter, S., Givon, U., et al. (2021) · Multiple Sclerosis Journal · doi:10.1177/13524585211003476 · Cited by 215
Circulating SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
Garcia-Beltran, W., Lam, E. C., Denis, K. J. S., et al. (2021) · medRxiv · doi:10.1101/2021.02.14.21251704 · Cited by 781
COVID-19 vaccine efficacy and effectiveness—the elephant (not) in the room
Olliaro, P., Torreele, E., & Vaillant, M. (2021) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00069-0 · Cited by 214
Immunogenicity and efficacy of heterologous ChAdOx1–BNT162b2 vaccination
Pozzetto, B., Legros, V., Djebali, S., Barateau, V., Guibert, N., Villard, M., Peyrot, L., Allatif, O., Fassier, J.-B., Massardier-Pilonchéry, A., et al. (2021) · Nature · doi:10.1038/s41586-021-04120-y · Cited by 210
COVID-19 Vaccination Hesitancy among Healthcare Workers—A Review
Peterson, C. J., Lee, B., & Nugent, K. (2022) · Vaccines · doi:10.3390/vaccines10060948 · Cited by 212
Rahmani, K., Shavaleh, R., Forouhi, M., Disfani, H. F., Kamandi, M., Oskooi, R. K., Foogerdi, M., Soltani, M., Rahchamani, M., Mohaddespour, M., et al. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.873596 · Cited by 204
Lapuente, D., Fuchs, J., Willar, J., Vieira Antão, A., Eberlein, V., Uhlig, N., Issmail, L., Schmidt, A., Oltmanns, F., Peter, A. S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27063-4 · Cited by 209
Wang, S., Liang, B., Wang, W., Li, L., Feng, N., Zhao, Y., Wang, T., Yan, F., Yang, S., & Xia, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01408-5 · Cited by 211
“For example, results from numerous clinical trials of licensed SARS-CoV-2 vaccines have shown lower efficacy in older adults than in younger adults.(11,475,476) While dNS1-RBD, an IN-delivered COVID-19 vaccine, was well tolerated in all participants aged 18–86 years, and immunogenicity in older adults (aged ≥60 years)…”
ResultEffect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies
Sormani, M. P., Inglese, M., Schiavetti, I., Carmisciano, L., Laroni, A., Lapucci, C., Da Rin, G., Serrati, C., Gandoglia, I., Tassinari, T., et al. (2021) · eBioMedicine · doi:10.1016/j.ebiom.2021.103581 · Cited by 227
Polymeric delivery systems for nucleic acid therapeutics: Approaching the clinic
van den Berg, A. I. S., Yun, C.-O., Schiffelers, R. M., & Hennink, W. E. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.01.014 · Cited by 208
Myocarditis After BNT162b2 and mRNA-1273 Vaccination
Larson, K. F., Ammirati, E., Adler, E. D., Cooper, L. T., Hong, K. N., Saponara, G., Couri, D., Cereda, A., Procopio, A., Cavalotti, C., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.055913 · Cited by 207
Cornberg, M., Buti, M., Eberhardt, C. S., Grossi, P. A., & Shouval, D. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.01.032 · Cited by 207
Galmiche, S., Luong Nguyen, L. B., Tartour, E., de Lamballerie, X., Wittkop, L., Loubet, P., & Launay, O. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.09.036 · Cited by 205
Greenhawt, M., Abrams, E. M., Shaker, M., Chu, D. K., Khan, D., Akin, C., Alqurashi, W., Arkwright, P., Baldwin, J. L., Ben-Shoshan, M., et al. (2021) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2021.06.006 · Cited by 204
Overview of SARS-CoV-2 infection in adults living with HIV
Ambrosioni, J., Blanco, J. L., Reyes-Urueña, J. M., Davies, M.-A., Sued, O., Marcos, M. A., Martínez, E., Bertagnolio, S., Alcamí, J., Miro, J. M., et al. (2021) · The Lancet HIV · doi:10.1016/s2352-3018(21)00070-9 · Cited by 206
Bernal, J. L., Andrews, N., Gower, C., Stowe, J., Robertson, C., Tessier, E., Simmons, R., Cottrell, S., Roberts, R., O’Doherty, M., et al. (2021) · doi:10.1101/2021.03.01.21252652 · Cited by 1,389
“6% in the early post-vaccination period.(6) Furthermore, with other vaccines an extended interval between the prime and booster doses typically provides a better immune response to the booster dose.”
BackgroundMethodRozen-Zvi, B., Yahav, D., Agur, T., Zingerman, B., Ben-Zvi, H., Atamna, A., Tau, N., Mashraki, T., Nesher, E., & Rahamimov, R. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.04.028 · Cited by 200
Nanomaterial surface modification toolkit: Principles, components, recipes, and applications
Kaymaz, S. V., Nobar, H. M., Sarıgül, H., Soylukan, C., Akyüz, L., & Yüce, M. (2023) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2023.103035 · Cited by 205
Cai, Q., He, B., Wang, S., Fletcher, S., Niu, D., Mitter, N., Birch, P. R. J., & Jin, H. (2021) · Annual Review of Plant Biology · doi:10.1146/annurev-arplant-081720-010616 · Cited by 207
Angel, Y., Spitzer, A., Henig, O., Saiag, E., Sprecher, E., Padova, H., & Ben-Ami, R. (2021) · JAMA · doi:10.1001/jama.2021.7152 · Cited by 202
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety
Fendler, A., de Vries, E. G. E., GeurtsvanKessel, C. H., Haanen, J. B., Wörmann, B., Turajlic, S., & von Lilienfeld-Toal, M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00610-8 · Cited by 204
Gagne, M., Moliva, J. I., Foulds, K. E., Andrew, S. F., Flynn, B. J., Werner, A. P., Wagner, D. A., Teng, I.-T., Lin, B. C., Moore, C., et al. (2022) · Cell · doi:10.1016/j.cell.2022.03.038 · Cited by 200
“…vaccines BNT162b2 andmRNA-1273 provide highly effective protection against symptomatic and severe infection with ancestral SARS-CoV-2 (Baden et al., 2021b; 1556 Cell 185, 1556–1571, April 28, 2022 Published by Elsevier Inc. Dagan et al., 2021; Pilishvili et al., 2021; Polack et al., 2020).”
Protection against Covid-19 by BNT162b2 Booster across Age Groups
Bar-On, Y. M., Goldberg, Y., Mandel, M., Bodenheimer, O., Freedman, L., Alroy-Preis, S., Ash, N., Huppert, A., & Milo, R. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2115926 · Cited by 202
Moor, M. B., Suter-Riniker, F., Horn, M. P., Aeberli, D., Amsler, J., Möller, B., Njue, L. M., Medri, C., Angelillo-Scherrer, A., Borradori, L., et al. (2021) · The Lancet Rheumatology · doi:10.1016/s2665-9913(21)00251-4 · Cited by 201
The SARS-CoV-2 mutations versus vaccine effectiveness: New opportunities to new challenges
Malik, J. A., Ahmed, S., Mir, A., Shinde, M., Bender, O., Alshammari, F., Ansari, M., & Anwar, S. (2022) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2021.12.014 · Cited by 201
Sallam, M., Dababseh, D., Eid, H., Hasan, H., Taim, D., Al-Mahzoum, K., Al-Haidar, A., Yaseen, A., Ababneh, N. A., Assaf, A., et al. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18052407 · Cited by 200
Abu-Raddad, L. J., Chemaitelly, H., Coyle, P., Malek, J. A., Ahmed, A. A., Mohamoud, Y. A., Younuskunju, S., Ayoub, H. H., Kanaani, Z. A., Kuwari, E. A., et al. (2021) · doi:10.1101/2021.01.15.21249731 · Cited by 201
Modelling optimal vaccination strategy for SARS-CoV-2 in the UK
Moore, S., Hill, E. M., Dyson, L., Tildesley, M. J., & Keeling, M. J. (2021) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1008849 · Cited by 196
SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses
Walls, A. C., Sprouse, K. R., Bowen, J. E., Joshi, A., Franko, N., Navarro, M. J., Stewart, C., Cameroni, E., McCallum, M., Goecker, E. A., et al. (2022) · Cell · doi:10.1016/j.cell.2022.01.011 · Cited by 196
“clinical trial evaluation of COVID-19 vaccines (Baden et al., 2021; Polack et al., 2020).”
InfluentialTalotta, R. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108665 · Cited by 199
Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited
Ribas, A., Sengupta, R., Locke, T., Zaidi, S. K., Campbell, K. M., Carethers, J. M., Jaffee, E. M., Wherry, E. J., Soria, J.-C., & D'Souza, G. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1817 · Cited by 198
Detailed Dissection and Critical Evaluation of the Pfizer/BioNTech and Moderna mRNA Vaccines
Xia, X. (2021) · Vaccines · doi:10.3390/vaccines9070734 · Cited by 201
“The two most frequently used SARS-CoV-2 vaccines, from Pfizer/BioNTech [1] and Moderna [2], respectively, are both mRNA vaccines.”
MethodElliott, P., Haw, D., Wang, H., Eales, O., Walters, C. E., Ainslie, K. E. C., Atchison, C., Fronterre, C., Diggle, P. J., Page, A. J., et al. (2021) · Science · doi:10.1126/science.abl9551 · Cited by 193
Activation or exhaustion of CD8+ T cells in patients with COVID-19
Rha, M.-S., & Shin, E.-C. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00750-4 · Cited by 194
Ferdinands, J. M., Rao, S., Dixon, B. E., Mitchell, P. K., DeSilva, M. B., Irving, S. A., Lewis, N., Natarajan, K., Stenehjem, E., Grannis, S. J., et al. (2022) · BMJ · doi:10.1136/bmj-2022-072141 · Cited by 185
Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunity
Rodda, L. B., Morawski, P. A., Pruner, K. B., Fahning, M. L., Howard, C. A., Franko, N., Logue, J., Eggenberger, J., Stokes, C., Golez, I., et al. (2022) · Cell · doi:10.1016/j.cell.2022.03.018 · Cited by 195
“…blood mononuclear cells (PBMCs) from 24 SARS-CoV-2 N and 30 SARS-CoV-2 PI individuals before vaccination and 1 week, 3 months, and 6 months after two vaccinations with BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) COVID-19 vaccines (Figure 1A; Table 1; Baden et al., 2020; Polack et al., 2020).”
MethodArtificial intelligence-driven rational design of ionizable lipids for mRNA delivery
Wang, W., Chen, K., Jiang, T., Wu, Y., Wu, Z., Ying, H., Yu, H., Lu, J., Lin, J., & Ouyang, D. (2024) · Nature Communications · doi:10.1038/s41467-024-55072-6 · Cited by 201
August, A., Attarwala, H. Z., Himansu, S., Kalidindi, S., Lu, S., Pajon, R., Han, S., Lecerf, J.-M., Tomassini, J. E., Hard, M., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01573-6 · Cited by 196
Pilishvili, T., Fleming-Dutra, K. E., Farrar, J. L., Gierke, R., Mohr, N. M., Talan, D. A., Krishnadasan, A., Harland, K. K., Smithline, H. A., Hou, P. C., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7020e2 · Cited by 191
Pregnancy and birth outcomes after SARS-CoV-2 vaccination in pregnancy
Theiler, R. N., Wick, M., Mehta, R., Weaver, A. L., Virk, A., & Swift, M. (2021) · American Journal of Obstetrics & Gynecology MFM · doi:10.1016/j.ajogmf.2021.100467 · Cited by 192
“The composite outcome, the Adverse Outcome Index (AOI), was calculated as a composite of any of the following events during the delivery hospitalization: (1) maternal death during hospitalization; (2) intrapartum neonatal death within 7 days of birth with a birthweight of ≥2500 g and ≥37 weeks’ gestation; (3) hypoxic-…”
Agha, M. E., Blake, M., Chilleo, C., Wells, A., & Haidar, G. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab353 · Cited by 191
Kounis, N. G., Koniari, I., de Gregorio, C., Velissaris, D., Petalas, K., Brinia, A., Assimakopoulos, S. F., Gogos, C., Kouni, S. N., Kounis, G. N., et al. (2021) · Vaccines · doi:10.3390/vaccines9030221 · Cited by 192
Piperazine-derived lipid nanoparticles deliver mRNA to immune cells in vivo
Ni, H., Hatit, M. Z. C., Zhao, K., Loughrey, D., Lokugamage, M. P., Peck, H. E., Cid, A. D., Muralidharan, A., Kim, Y., Santangelo, P. J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32281-5 · Cited by 192
Microneedles: A New Generation Vaccine Delivery System
Menon, I., Bagwe, P., Gomes, K. B., Bajaj, L., Gala, R., Uddin, M. N., D’Souza, M. J., & Zughaier, S. M. (2021) · Micromachines · doi:10.3390/mi12040435 · Cited by 192
Giordano, G., Colaneri, M., Di Filippo, A., Blanchini, F., Bolzern, P., De Nicolao, G., Sacchi, P., Colaneri, P., & Bruno, R. (2021) · Nature Medicine · doi:10.1038/s41591-021-01334-5 · Cited by 192
de Alwis, R., Gan, E. S., Chen, S., Leong, Y. S., Tan, H. C., Zhang, S. L., Yau, C., Low, J. G. H., Kalimuddin, S., Matsuda, D., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.04.001 · Cited by 191
Jena, A., Mishra, S., Deepak, P., Kumar-M, P., Sharma, A., Patel, Y. I., Kennedy, N. A., Kim, A. H. J., Sharma, V., & Sebastian, S. (2022) · Autoimmunity Reviews · doi:10.1016/j.autrev.2021.102927 · Cited by 192
(2021) · doi:10.1038/s41467-021-25167-5 · Cited by 216
Self-citationAdaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2
Israelow, B., Mao, T., Klein, J., Song, E., Menasche, B., Omer, S. B., & Iwasaki, A. (2021) · Science Immunology · doi:10.1126/sciimmunol.abl4509 · Cited by 189
“Phase III vaccine clinical trials as well as post-marketing vaccine effectiveness studies provide evidence of the development of protective immunity in humans (13, 14).”
The humoral response and antibodies against SARS-CoV-2 infection
Qi, H., Liu, B., Wang, X., & Zhang, L. (2022) · Nature Immunology · doi:10.1038/s41590-022-01248-5 · Cited by 191
Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273
Teo, S. P. (2022) · Journal of Pharmacy Practice · doi:10.1177/08971900211009650 · Cited by 191
“Although the duration of protection from a singledose remains uncertain, a second dose does not appear to confer much additional benefit for the vaccine recipients.(29) In the Moderna trial, 81 (0.”
BackgroundPawlowski, C., Lenehan, P., Puranik, A., Agarwal, V., Venkatakrishnan, A. J., Niesen, M. J. M., O’Horo, J. C., Virk, A., Swift, M. D., Badley, A. D., et al. (2021) · Med · doi:10.1016/j.medj.2021.06.007 · Cited by 187
ANCA-Associated Vasculitis Following Pfizer-BioNTech COVID-19 Vaccine
Shakoor, M. T., Birkenbach, M. P., & Lynch, M. (2021) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.06.016 · Cited by 190
“Common adverse events include mild-to-moderate tenderness at the injection site, fever, fatigue, body aches, and headaches.(2,3) Reports of anaphylaxis to COVID-19 vaccines also started to surface soon after the COVID-19 vaccination campaign began,(4,5) but long-term sequalae of the vaccines remain unknown.”
BackgroundPeripheral Nervous System Manifestations Associated with COVID-19
Andalib, S., Biller, J., Di Napoli, M., Moghimi, N., McCullough, L. D., Rubinos, C. A., O’Hana Nobleza, C., Azarpazhooh, M. R., Catanese, L., Elicer, I., et al. (2021) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-021-01102-5 · Cited by 190
COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies
Raman, R., Patel, K. J., & Ranjan, K. (2021) · Biomolecules · doi:10.3390/biom11070993 · Cited by 188
“1% percent respectively in preventing COVID-19 illness [88,89].”
BackgroundResultAdaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2
Israelow, B., Mao, T., Klein, J., Song, E., Menasche, B., Omer, S. B., & Iwasaki, A. (2021) · doi:10.1101/2021.05.19.444825 · Cited by 189
Simon, D., Tascilar, K., Fagni, F., Krönke, G., Kleyer, A., Meder, C., Atreya, R., Leppkes, M., Kremer, A. E., Ramming, A., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-220461 · Cited by 185
Shrotri, M., Krutikov, M., Palmer, T., Giddings, R., Azmi, B., Subbarao, S., Fuller, C., Irwin-Singer, A., Davies, D., Tut, G., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00289-9 · Cited by 185
(2021) · doi:10.1016/j.eclinm.2021.100861 · Cited by 201
“Remarkably, this efficacy estimate is similar to the efficacy reported for the two mRNA COVID-19 vaccines [18,19], our earlier reinfection study [5], and a study of reinfection in Switzerland [45], but is higher than that reported recently in other studies of reinfection, ranging between 80 and 90% [40 44,46].”
Public health impact of covid-19 vaccines in the US: observational study
Suthar, A. B., Wang, J., Seffren, V., Wiegand, R. E., Griffing, S., & Zell, E. (2022) · BMJ · doi:10.1136/bmj-2021-069317 · Cited by 185
Mucosal immune response in biology, disease prevention and treatment
Zhou, X., Wu, Y., Zhu, Z., Lu, C., Zhang, C., Zeng, L., Xie, F., Zhang, L., & Zhou, F. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02043-4 · Cited by 186
COVID-19 vaccine acceptance among pregnant, breastfeeding, and nonpregnant reproductive-aged women
Sutton, D., D'Alton, M., Zhang, Y., Kahe, K., Cepin, A., Goffman, D., Staniczenko, A., Yates, H., Burgansky, A., Coletta, J., et al. (2021) · American Journal of Obstetrics & Gynecology MFM · doi:10.1016/j.ajogmf.2021.100403 · Cited by 185
“Statistical analysis Participants’ characteristics were summarized for the overall sample and by group of pregnancy status into 3 categories: (1) nonpregnant nonbreastfeeding respondents, (2) nonpregnant breastfeeding respondents, and (3) pregnant respondents.”
BackgroundMethodXia, S., Zhang, Y., Wang, Y., Wang, H., Yang, Y., Gao, G. F., Tan, W., Wu, G., Xu, M., Lou, Z., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00462-x · Cited by 186
Waissengrin, B., Agbarya, A., Safadi, E., Padova, H., & Wolf, I. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00155-8 · Cited by 185
Polymer‐Based mRNA Delivery Strategies for Advanced Therapies
Yang, W., Mixich, L., Boonstra, E., & Cabral, H. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202202688 · Cited by 186
Momin, T., Kansagra, K., Patel, H., Sharma, S., Sharma, B., Patel, J., Mittal, R., Sanmukhani, J., Maithal, K., Dey, A., et al. (2021) · eClinicalMedicine · doi:10.1016/j.eclinm.2021.101020 · Cited by 185
“The results of few phase 3 trials have also been published now [8,9].”
Walls, A. C., Miranda, M. C., Schäfer, A., Pham, M. N., Greaney, A., Arunachalam, P. S., Navarro, M.-J., Tortorici, M. A., Rogers, K., O’Connor, M. A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.09.015 · Cited by 185
(2021) · doi:10.1101/2021.08.24.21262415 · Cited by 283
“Exposure variable: study groups The eligible study population was divided into three groups: (1)fully vaccinated and SARS-CoV-2-naïve individuals, namely MHS members who received two doses of the BioNTech/Pfizer mRNA BNT162b2 vaccine by February 28, 2021, did not receive the third dose by the end of the study period a…”
Chodick, G., Tene, L., Patalon, T., Gazit, S., Ben Tov, A., Cohen, D., & Muhsen, K. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.15985 · Cited by 181
Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors
Pérez-Alós, L., Armenteros, J. J. A., Madsen, J. R., Hansen, C. B., Jarlhelt, I., Hamm, S. R., Heftdal, L. D., Pries-Heje, M. M., Møller, D. L., Fogh, K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29225-4 · Cited by 185
Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset
Kalimuddin, S., Tham, C. Y. L., Qui, M., de Alwis, R., Sim, J. X. Y., Lim, J. M. E., Tan, H.-C., Syenina, A., Zhang, S. L., Le Bert, N., et al. (2021) · Med · doi:10.1016/j.medj.2021.04.003 · Cited by 188
Combinatorial development of nebulized mRNA delivery formulations for the lungs
Jiang, A. Y., Witten, J., Raji, I. O., Eweje, F., MacIsaac, C., Meng, S., Oladimeji, F. A., Hu, Y., Manan, R. S., Langer, R., et al. (2024) · Nature Nanotechnology · doi:10.1038/s41565-023-01548-3 · Cited by 185
“Most notably, intra-muscularly delivered lipid nanoparticle (LNP)-based mRNA vaccines have showed excellent efficacy against the SARS-CoV-2 virus driving the COVID-19 pandemic 13,14 .”
Impact of the COVID-19 pandemic on publication dynamics and non-COVID-19 research production
Raynaud, M., Goutaudier, V., Louis, K., Al-Awadhi, S., Dubourg, Q., Truchot, A., Brousse, R., Saleh, N., Giarraputo, A., Debiais, C., et al. (2021) · BMC Medical Research Methodology · doi:10.1186/s12874-021-01404-9 · Cited by 183
“Nevertheless, these findings should be interpreted in the light of the efforts made around COVID-19, in particular the commitment around the estimation of COVID-19 cases and related deaths worldwide [1], the implementation of massive, international collaborations [4], the fast-tracking process of COVID-19 medical rese…”
BackgroundCOVID-19 Vaccination and Glomerulonephritis
Klomjit, N., Alexander, M. P., Fervenza, F. C., Zoghby, Z., Garg, A., Hogan, M. C., Nasr, S. H., Minshar, M. A., & Zand, L. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.09.008 · Cited by 183
“- Relapse case s/p 1st dose — 1 (1, 2) 1 (1, 2)”
InfluentialRosenblum, H. G., Gee, J., Liu, R., Marquez, P. L., Zhang, B., Strid, P., Abara, W. E., McNeil, M. M., Myers, T. R., Hause, A. M., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00054-8 · Cited by 182
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.